Pharma channel feed

#AS­CO21: No­var­tis keeps build­ing out sur­vival da­ta for Kisqali, hop­ing to add pres­sure on Pfiz­er's Ibrance

4 years ago
R&D

Glax­o­SmithK­line scores a win in Zofran case af­ter FDA re­peat­ed­ly said preg­nan­cy risk da­ta did not re­quire la­bel changes

4 years ago
FDA+

Lock­ing horns with Ab­b­Vie, J&J boasts post-TNF da­ta for next-gen drug Trem­fya in pso­ri­at­ic arthri­tis

4 years ago

Ab­b­Vie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its ex­pan­sion plans

4 years ago

Biden HHS seeks to dis­miss PhRMA’s law­suit to stop Cana­di­an drug im­ports

4 years ago
FDA+

No­var­tis scraps a slate of Beovu tri­als af­ter 4-week dos­ing turned up safe­ty is­sues — dash­ing hopes of de­thron­ing Eylea

4 years ago
R&D

Sanofi slash­es an­oth­er pro­gram for key mol­e­cule, while keep­ing hopes in hand­ful of rare dis­eases

4 years ago
R&D

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

4 years ago
FDA+

Bio­haven earns pre­ven­ta­tive nod for mi­graine med Nurtec, snar­ing a much-need­ed leg up over Ab­b­Vie

4 years ago
FDA+

FDA ad­comm votes in fa­vor of ap­prov­ing Proven­tion Bio’s drug to de­lay type 1 di­a­betes

4 years ago
FDA+

El­liott is back­ing away from a threat­ened ac­tivist at­tack on Glax­o­SmithK­line, giv­ing CEO Em­ma Walm­s­ley some breath­ing room — re­port

4 years ago

US paus­es use of Eli Lil­ly Covid-19 mAb com­bo in six more states due to vari­ants from Brazil, In­dia

4 years ago
Coronavirus

As FDA clears re­l­u­golix for uter­ine fi­broids, My­ovant, Pfiz­er gear up to take on Ab­b­Vie in com­mer­cial ri­val­ry

4 years ago
FDA+

‘In­ac­cu­ra­cies’ push FDA to re­verse Trump-era ter­mi­na­tion of its Un­ap­proved Drugs Ini­tia­tive

4 years ago
FDA+

Proven­tion Bio roller­coast­er con­tin­ues with gen­er­al­ly pos­i­tive re­marks from FDA ahead of Thurs­day’s ad­comm

4 years ago
FDA+

Days af­ter FDA clears C3 drug, Apel­lis spot­lights ex-US PhI­II win among pa­tients who haven't tak­en Soliris

4 years ago
R&D

UK be­gins in­quiry in­to As­traZeneca's $39B buy­out of Alex­ion

4 years ago
Deals

Ab­b­Vie’s last stand: How an Ice­landic bil­lion­aire’s biosim­i­lar has one fi­nal shot to de­throne Hu­mi­ra

4 years ago

Bris­tol My­er­s' Op­di­vo leads the pack with FDA ap­proval for re­sect­ed esophageal or GEJ can­cer

4 years ago
FDA+

Blue­bird’s new gene ther­a­py among three new EMA OKs ahead of FDA

4 years ago
Cell/Gene Tx
FDA+

Sting­ing from a proxy loss and hun­gry for cash, Glax­o­SmithK­line bails on eq­ui­ty stake in In­no­vi­va for a tidy $392M

4 years ago

Eli Lil­ly sues HHS to halt any 340B-re­lat­ed mon­e­tary penal­ties

4 years ago
FDA+

#AS­CO21: Bris­tol My­ers takes home the win in 1st late-stage study for LAG-3 path­way, set­ting up a US fil­ing

4 years ago
R&D

FDA ad­comm to re­view Fi­bro­Gen’s chron­ic kid­ney dis­ease drug in Ju­ly

4 years ago
FDA+
First page Previous page 239240241242243244245 Next page Last page
A service from the Financial Times